Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma

Tuesday, October 31, 2017 Heart Disease News
Email Print This Page Comment bookmark
Font : A-A+

First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels or any other Type 2 biomarkers at baseline

Sanofi Contacts:

Media Relations

Investor Relations

Ashleigh Koss

George Grofik

Tel: +1 908 981 8745

Tel. +33 (0)1 53 77 45 45

[email protected]

[email protected]

Regeneron Contacts:

Media Relations

Investor Relations

Arleen Goldenberg

Manisha Narasimhan, Ph.D.

Tel: +1 (914) 847-3456

Tel: 1 (914) 847-5126

Mobile: +1 (914) 260-8788

[email protected]

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store